Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 1.00 |
| ▸ | HCRTR2 | O43614 | 20/20 | 1.00 |
| ▸ | TSPO | P30536 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29912233 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1778119 | 0.98 | HCRTR2 (0.95) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL29515976 | 0.94 | HCRTR1 (1.00) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL21018247 | 0.92 | HCRTR1 (0.85) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1777087 | 0.91 | HCRTR1 (0.83) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1777506 | 0.90 | HCRTR1 (0.81) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1777860 | 0.89 | HCRTR1 (0.81) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1777864 | 0.89 | HCRTR1 (0.81) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1780213 | 0.87 | HCRTR1 (0.78) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1778578 | 0.87 | HCRTR1 (0.77) | HCRTR1HCRTR2TSPOOPRK1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | claimed |
| CN-122031471-A | Application of SB-408124 in preparation of medicine for delaying thymus recession | 三峡大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| US-12441709-B2 | Therapeutic compounds | INDIVIOR UK LIMITED (GB) | 2025-10-14 | — | — | US | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-04 | — | — | US | disclosed |
| CN-111315734-B | Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists | 克罗诺斯治疗有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240076282-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2024-03-07 | — | — | US | disclosed |
| WO-2023218023-A1 | THIAZOLOARYL-METHYL SUBSTITUTED CYCLIC HYDRAZINE-N-CARBOXAMIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-11-16 | — | — | WO | disclosed |
| EP-4272824-A2 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-11-08 | — | — | EP | disclosed |
| WO-2011050202-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050198-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
| US-20100234417-A1 | THYROTROPIN RELEASING HORMONE RECEPTOR-OREXIN RECEPTOR HETERO-DIMERS/-OLIGOMERS | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2010-09-16 | — | — | US | disclosed |
| WO-2010031114-A1 | NOVEL RECEPTOR HETERO-DIMERS/-OLIGOMERS | DIMERIX BIOSCIENCE PTY LTD (AU) | 2010-03-25 | — | — | WO | disclosed |
| US-20100021457-A1 | DETECTION SYSTEM AND USES THEREFOR | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2010-01-28 | — | — | US | disclosed |
| EP-2080012-A1 | DETECTION SYSTEM AND USES THEREFOR | Dimerix Bioscience Pty.Ltd. (AU) | 2009-07-22 | — | — | EP | disclosed |
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. | 2009-03-26 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| WO-2008055313-A1 | DETECTION SYSTEM AND USES THEREFOR | DIMERIX BIOSCIENCE PTY LTD (AU) | 2008-05-15 | — | — | WO | disclosed |
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885TSPO 408/4885 |
| US-20240076282-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885TSPO 270/4885 |
| US-20240109901-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885TSPO 267/4885 |
| US-12441709-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885TSPO 270/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885TSPO 267/4885 |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885TSPO 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.